(Reuters) -Shares of Dr Reddy's Laboratories dropped 6% on Friday and were on track for their worst session in nearly nine ...

BENGALURU/HYDERABAD (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported third-quarter profit below expectations on Thursday, hurt by pricing pressure in the competitive North American ...

Ashraf Z. Badros, MB, ChB, discusses the results of the phase 3 AURIGA trial which evaluated daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

Indian generic drugmaker Dr Reddys Laboratories expressed optimism about the Donald Trump administration on Thursday, citing ...

Lenalidomide, an analog of thalidomide, was developed because of its more potent anti-MM activity and better toxicity profile than the parent compound. Since its introduction in 2004, lenalidomide ...

The phase 3 AURIGA study evaluated daratumumab (Darzalex) and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma who were in very good partial response, minimal ...

The company's North American revenue has seen a decline of over 9%. One of the primary worries is the reduction in revenues ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...